Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2025New Zealand medical journal

Are cannabinoids with cancer immunotherapy contributing to early death? A call for caution and further study

View Full Paper
Ask AI
Bookmark
Share

Authors

BJBart Jansen

Discussion

Loading...

Member takes

Overview

This review reveals potential risks of cannabinoids reducing treatment efficacy in cancer immunotherapy, suggesting careful evaluation of patient care.

Key Points

  • Cannabis use for symptom management in cancer is common, raising concerns over its impact on immunotherapy.
  • Recent studies indicate lower response rates and reduced survival in patients using cannabis with immunotherapy.
  • There are significant methodological issues and demographic differences in studies assessing cannabis interactions.
  • Clinicians must balance symptom relief benefits with risks of treatment interactions and ensure patient awareness of potential implications.

Cite This Study

Bart Jansen (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd9c9https://doi.org/10.26635/6965.6986
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome2020 · 138 citations
  2. 2Commentary on Bar-Sela et al. Cannabis Consumption Used by Cancer Patients During Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 24472025
  3. 3Analyzing the medical use of cannabis for cancer patients: a critical perspective2024 · 1 citations
  4. 4Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis2025 · 8 citations
  5. 5Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?2024 · 4 citations